Investor News

1 - 10

11 - 20

21 - 30

31 - 40

41 - 50

March 25, 2019

Bayer reaches settlement to resolve Xarelto™ litigation

March 19, 2019

Bayer statement on jury's decision in phase one of California glyphosate trial

March 08, 2019

Not intended for U.S. and UK Media

Bayer submits European marketing authorization application for darolutamide

March 05, 2019

Not intended for U.S. and UK Media

Bayer submits darolutamide for marketing authorization in Japan

February 27, 2019

Fiscal 2018:

Bayer increases sales and earnings - leader in agriculture after acquisition

February 27, 2019

Not intended for U.S. and UK Media

Bayer completes rolling submission for darolutamide in U.S.

February 26, 2019

Bayer proposes dividend for 2018 of 2.80 euros per share

February 15, 2019

Not intended for U.S. and UK Media

Bayer exercised option to obtain full licensing rights for larotrectinib and BAY 2731954 (LOXO-195)

February 14, 2019

Not intended for U.S. and UK Media - American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) 2019

Bayer's darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer

January 08, 2019

New predictive seed placement technology delivers strong results in 2018:

Bayer expands digital innovation pipeline at The Climate Corporation to bring breakthrough digital tools to more farmers

1 - 10

11 - 20

21 - 30

31 - 40

41 - 50

Previous News can be found in the Archive

Services

Current Event

December 10, 2019

Investor Conference Call: Bayer 2030 Sustainable Development Objectives

Overview

Current Links

IR News Archive Overview

Download Acrobat Reader

Email Newsletter

RSS Newsfeed

Last updated: February 15, 2019

Investor News

Services

Download Center

Current Event

Current Links